Shares of Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) dropped 9.4% during mid-day trading on Thursday. The company traded as low as $0.77 and last traded at $0.77. 20,000 shares changed hands during trading, a decline of 9% from the average daily volume of 21,902 shares. The stock had previously closed at $0.85.
Avacta Group Stock Performance
The company has a 50 day moving average price of $0.91 and a 200 day moving average price of $0.92.
About Avacta Group
Avacta Group is a UK-based biotechnology company focused on developing cancer therapies. Its proprietary pre|CISION platform is designed to keep drug payloads inactive in circulation and activate them within the tumor environment, with the goal of concentrating treatment at the tumor site.
The company’s clinical-stage pipeline includes AVA6000, a doxorubicin prodrug designed to be activated by an enzyme found in many tumors. Avacta has also developed Affimer, an engineered protein-binding technology, and has pursued diagnostic applications alongside its earlier research activities.
Avacta’s work is centered on drug development, with clinical research and operations based in the United Kingdom.
Further Reading
- Five stocks we like better than Avacta Group
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
